1269-Blood Proteomic Signatures of NSCLC Surgical

This study investigates the use of blood proteomics to identify non-invasive biomarkers for non-small cell lung cancer (NSCLC). Researchers utilized the SomaScan and NULISA platforms to analyze protein signatures in patients undergoing surgery or immunotherapy. The findings highlight specific proteins, such as MUC16 and IL-6, which can predict tumor recurrence, treatment response, and overall survival rates. By comparing different proteomic technologies, the authors demonstrated that plasma monitoring offers a robust method for real-time clinical assessment. This multi-platform approach reveals how systemic inflammation and immune regulation influence patient outcomes. Ultimately, these circulating biomarkers provide a promising diagnostic tool to complement traditional imaging for better disease management.References:Yaghoubi Naei V, Kilgallon A, Mendes G, et al. Dissecting non-small cell lung cancer (NSCLC) with blood proteomics—from surgical to immunotherapeutic responses[J]. npj Precision Oncology, 2026.前往小宇宙评论区与主播互动